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Despite its name, tissue factor pathway inhibitor-2
(TFPI-2) poorly inhibits tissue factor (TF) and as yet
has no defined physiologic function. Originally cloned
from a human placental cDNA library while seeking
Kunitz-inhibitory domain proteins related to TFPI-1,
TFPI-2’s sequence matched that of placental protein 5
(PP5) and matrix serine protease inhibitor (MSPI),
described previously in dermal fibroblasts as well as in
placental and endothelial cells (ECs) (1–3). Although a
molecular weight of 25 kDa was originally proposed for
the unglycosylated protein, immunoreactive TFPI-2
typically migrates with an apparent molecular weight
of 27, 31, and 33 kDa due to differential glycosylation
(1, 4). Cloning of TFPI-2 revealed similarities in the
overall domain organization as well as considerable
amino acid sequence homology with TFPI-1, an impor-
tant regulator of the extrinsic pathway of blood coag-
ulation via its inhibition of factor Xa and factor
VIIa/TF complex (1).Nevertheless, TFPI-2 only weakly
inhibits these coagulation proteins. Though estab-
lished targets of TFPI-2 include certain other serine
proteases, e.g., kallikrein, trypsin, chymotrypsin, and
plasmin, its biological function remains uncertain (1,
2, 5). Curiously, most of the TFPI-2 expressed by ECs of
various origins localizes within the ECM (4).
Turnover of the arterial ECM contributes crucially to
a variety of diseases, including atherosclerosis (6). Inter-
stitial collagen, comprising up to 60% of the total pro-
tein of plaques, confers stability on the lesion’s fibrous
cap that separates the procoagulant lipid core from the
blood (7, 8). In plaques that have ruptured, the fibrous
cap of the plaque’s shoulder region, the prototypical
site of rupture, has particularly sparse collagen (9, 10).
Thus, the balance between matrix conservation and
matrix degradation probably determines plaque stabil-
ity and thereby the risk of acute clinical complications
such as myocardial infarction and stroke.
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Degradation of ECM, particularly interstitial collagen, promotes plaque instability, rendering athero-
ma prone to rupture. Previous studies implicated matrix metalloproteinases (MMPs) in these process-
es, suggesting that dysregulated MMP activity, probably due to imbalance with endogenous inhibitors,
promotes complications of atherosclerosis. We report here that the serine proteinase inhibitor tissue
factor pathway inhibitor-2 (TFPI-2) can function as an MMP inhibitor. TFPI-2 diminished the ability
of the interstitial collagenases MMP-1 and MMP-13 to degrade triple-helical collagen, the primary
load-bearing molecule of the ECM within human atheroma. In addition, TFPI-2 also reduced the activ-
ity of the gelatinases MMP-2 and MMP-9. In contrast to the “classical” tissue inhibitors of MMPs
(TIMPs), TFPI-2 expression in situ correlated inversely with MMP levels in human atheroma. TFPI-2
colocalized primarily with smooth muscle cells in the normal media as well as the plaque’s fibrous cap.
Conversely, the macrophage-enriched shoulder region, the prototypical site of matrix degradation and
plaque rupture, stained only weakly for TFPI-2 but intensely for gelatinases and interstitial collage-
nases. Evidently, human mononuclear phagocytes, an abundant source of MMPs within human
atheroma, lost their ability to express this inhibitor during differentiationin vitro. These findings
establish a new, anti-inflammatory function of TFPI-2 of potential pathophysiological significance
for human diseases, including atherosclerosis.
J. Clin. Invest. 107:1117–1126 (2001).A variety of proteases, including the matrix metallo-
proteinases (MMPs), degrade matrix macromolecules.
The MMP family encompasses at least 27 members
that share common structural elements and are typi-
cally released as inactive zymogens (11). Inflammatory
cytokines, such as interleukin-1 (IL-1), TNF-α, and
CD40 ligand (CD40L), induce the expression of MMPs
in various cell types, including ECs, smooth muscle
cells (SMCs), and mononuclear phagocytes (MØs)
(10–16). Attaining matrix-degrading activity requires
maturation of the MMP zymogen (17, 18).
However, the expression of mature MMPs does not
necessarily correlate with matrix-degrading activity
since endogenous inhibitors tightly regulate MMP
activity. Such endogenous inhibitors were considered
restricted to the family of tissue inhibitors of MMPs
(TIMPs) (19–25). Interestingly, expression of this pro-
totypical class of inhibitors does not correlate inverse-
ly with enhanced MMP activity in situ, as would be
expected with increased matrix turnover (26, 27). Addi-
tionally, certain TIMPs (e.g., TIMP-2) are implicated in
the membrane-type metalloproteinase–mediated (MT-
MMP–mediated) activation of distinct MMP family
members (e.g., MMP-2 and MMP-13), as well as in the
release of active MMPs (28, 29). Thus, operation of
inhibitory mechanisms beyond TIMPs has been postu-
lated in atheroma, although simple quantitative corre-
lation of MMP to TIMP probably does not adequately
reflect complex in vivo situations (e.g., local concen-
trations of matrix-degrading enzymes and their
inhibitors might vary due to compartmentalization;
see refs 30–32). Interestingly, previous work from sev-
eral groups implicated members of the serpin super-
family, i.e., α2-macroglobulin and RECK, in the regula-
tion of MMP activity (33–35).
In accordance with its prominent ECM localization
(4), previous reports suggested a matrix-protective
function for the serpin TFPI-2. TFPI-2 inhibited matrix
degradation and invasion by fibrosarcoma cells (36).
Rao et al. demonstrated that TFPI-2 concentration
dependently inhibited plasmin-dependent activation
of pro–MMP-1 and pro–MMP-3, though it was unclear
whether inhibition occurred because of binding to
plasmin or to MMPs (5). We hypothesized here that
TFPI-2 might act directly as an endogenous inhibitor
of active MMPs and that local TFPI-2 deficiency may
pertain to human atheroma.
Methods
Materials. Rabbit anti-human TFPI-2 Ab was prepared
as described previously (1). Recombinant human TFPI-
2 was expressed in hamster kidney cells transfected with
TFPI-2 cDNA and purified from serum-free condi-
tioned medium by a combination of heparin-agarose
chromatography, Mono Q FPLC, Mono S FPLC, and
Superose 12 FPLC (all from Amersham Pharmacia
Biotech Inc., Piscataway, New Jersey, USA). Purified
TFPI-2 migrated as a single band with an apparent
molecular weight of 32 kDa in SDS-PAGE under reduc-
ing (heat-inactivated) and nonreducing (non–heat-
treated) conditions (Figure 1h). The amino-terminal
sequence of recombinant TFPI-2 was identical to that
predicted from the cDNA. Human recombinant IL-1β
and TNF-α were obtained from Endogen Inc.(Cam-
bridge, Massachusetts, USA), and recombinant TIMP-1
was purchased from Calbiochem-Novabiochem Corp.
(La Jolla, California, USA). Human recombinant CD40L
was generated as described previously (37). Escherichia
coli endotoxin (LPS) was purchased from Sigma Chem-
ical Co. (St. Louis, Missouri, USA). MMP-2 zymogen
was purchased from Oncogene Research Products (San
Diego, California, USA). Polyclonal rabbit anti-human
MMP-1, -2, and -9 (Triple Point Biologics Inc., Portland,
Oregon, USA) as well as mouse anti-human MMP-13
(kindly provided by Carlos Lopez-Otin, University of
Oviedo, Oviedo, Spain) were used for immunohisto-
chemistry and Western blot analysis. Monoclonal
mouse anti-human TIMP-1 and TIMP-2 were obtained
from Calbiochem-Novabiochem Corp. Human recom-
binant cathepsin S and cathepsin K were kindly provid-
ed by Guo Ping-Shi (University of California, San Fran-
cisco, California, USA).
MMP-activity assays. Assays of MMP and cathepsin
activity employed either purified triple-helical type I col-
lagen (Chemicon International, Temecula, California,
USA) or self-quenching fluorophore-conjugated native
or synthetic substrates (Molecular Probes Inc., Eugene,
Oregon, USA; Chondrex LLC, Redmond, Washington,
USA; or Chemicon International). Analysis of MMP-1
and MMP-13 activity (both 10 µg/ml, provided as trun-
cated 41/44-kDa and 27-kDa forms, respectively;
Chemicon International) required activation via 1 mM
p-aminophenylmercuric acetate (APMA) for 2 hours.
MMP-2 and MMP-9 (both 10 µg/ml; Oncogene
Research Products) were provided as mature, active
enzymes (66 kDa and 83 kDa, respectively). To analyze
inhibition, MMPs were preincubated with the respective
concentrations of TFPI-2 for 1 hour at 37°C in reaction
buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM
CaCl2, 1 µM zinc chloride, 0.01% vol/vol BRIJ 35). The
time required for equilibration (30 minutes) was deter-
mined by following the progress of inhibition after mix-
ing MMP and TFPI-2. Subsequently, the respective
FITC-conjugated substrate was added (25°C) and enzy-
matic activity determined during the linear rate of the
reaction by continuous monitoring with a fluorescence
spectrophotometer at excitation and emission wave-
lengths of 495 nm and 515 nm, respectively. EC50values
were determined for the incubation of each of the
respective MMPs with TFPI-2. Reactions employing
nonconjugated collagen were analyzed by Western blot-
ting with an anti–type I collagen Ab. Inhibitory activity
of TFPI-2 against cathepsins was investigated by apply-
ing cathepsin S or K (both 10 µg/ml) to processing
assays identical in procedure to those described above
employing an acidic protease processing buffer (0.05%
Triton X-100, 20 mM sodium acetate, and 1 mM EDTA,
pH 5.5), as described previously (38).
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mined by dividing sample fluorescence intensity by the
value obtained with identical concentrations of MMP
without TFPI-2. For control purposes, TFPI-2 was
preincubated (1 hour, 37°C) with trypsin (Sigma
Chemical Co.) or VIIa/TF (American Diagnostica Inc.,
Greenwich, Connecticut, USA) or was replaced by
either recombinant TFPI-1 (American Diagnostica Inc.)
or TIMP-1. Additionally, heat-inactivated TFPI-2 (10
minutes, 95°C) was employed. Data are presented as
mean ± SD, obtained from duplicate determinations.
Western blot analysis. Samples were separated by stan-
dard SDS-PAGE under nonreducing conditions and
blotted to polyvinylidene difluoride membranes (Bio-
Rad Laboratories Inc., Hercules, California, USA)
using a semi-dry blotting apparatus (0.8 mA/cm2, 30
minutes; Bio-Rad Laboratories Inc.). Blots were
blocked (>2 hours) in 5% defatted dry milk/PBS/0.1%
Tween-20. After 1 hour of incubation with the pri-
mary Ab, blots were washed three times (PBS/0.1%
Tween), and the secondary, peroxidase-conjugated Ab
(Jackson ImmunoResearch, West Grove, Pennsylvania,
USA) was added for another hour. Finally, the blots
were washed three times (PBS/0.1% Tween) and
immunoreactive proteins were visualized using West-
ern blot chemiluminescent detection (NEN Life Sci-
ence Products Inc., Boston, Massachusetts, USA).
Cell isolation and culture. Human vascular SMCs were
isolated from human saphenous veins by explant out-
growth, and cultured in DMEM (BioWhittaker Inc.,
Walkersville, Maryland, USA) supplemented with 1% 
L-glutamine (BioWhittaker Inc.), 1% penicillin/strepto-
mycin (BioWhittaker Inc.), and 10% FBS (Atlanta Bio-
logicals Inc., Norcross, Georgia, USA). SMCs were 
cultured 24 hours before the experiment in in-
sulin/transferrin (IT) media lacking FBS, as described
previously (39). SMCs were routinely characterized by
immunostaining with anti-SMC α-actin Ab (Enzo
Diagnostics Inc., Farmingdale, New York, USA).
Mononuclear phagocytes were isolated by density-
gradient centrifugation and subsequent counterflow
elutriation from freshly prepared human PBMCs
obtained from leukopacs of healthy donors. The puri-
ty of mononuclear phagocytes was equal to or greater
than 96%, as determined by FACS analysis (anti-
human CD68 mAb FITC; PharMingen, San Diego,
California, USA). Cells were cultured in RPMI-1640
medium (BioWhittaker Inc.) containing 5% human
serum (Sigma Chemical Co.). Twenty-four hours
before stimulation, cells were incubated in serum-free
RPMI-1640 medium.
Culture media and FBS contained less than 40 pg/ml
endotoxin as determined by chromogenic Limulus
amoebocyte assay (QLC-1000; BioWhittaker Inc.).
Biochemical analysis of human atherosclerotic lesions.
Frozen tissue from five nonatherosclerotic aortae and
carotid arteries and 12 carotid plaques were
dichotomized into fibrous and atheromatous plaques
by morphological criteria as described previously (9).
The specimens were homogenized (Ultra-turrax T 25;
IKA-Labortechnik, Wilmington, North Carolina,
USA), lysed (0.3 g tissue/ml in 10 mM sodium phos-
phate, 150 mM NaCl, 1% Triton X-100, 0.1% SDS,
0.5% sodium deoxycholate, 0.2% sodium azide), clari-
fied (13,000 g, 15 minutes), and the protein concen-
tration determined using a bicinchoninic acid (BCA)
protein assay (Pierce Chemical Co., Rockford, Illinois,
USA). Fifty micrograms total protein were applied to
Western blot analysis.
Immunoprecipitation and zymography. Supernatants of
SMC cultures, or the respective recombinant MMP
preincubated with TFPI-2 (1 hour, 37°C), were incu-
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Figure 1
Human recombinant TFPI-2 (recTFPI-2) inhibits MMP activity. Human
recombinant MMP-1 (a, e), MMP-13 (b, f), MMP-2 (c), MMP-9 (d),
and cathepsin S or K (g) (all at 10 µg/ml) were incubated with the
respective concentrations of TFPI-2 (a–d, g) or TIMP-1 (e, f) (1 hour,
37°C), and the ability of the enzymes to process fluorophore-conju-
gated native (a, b, e, f) or peptide (c, d, g) substrate was measured as
described. Percentage of activity was normalized to the activity
obtained with the respective MMP lacking TFPI-2. Data shown repre-
sent mean ± SD and are representative of at least three independent
experiments. (h) Human recombinant TFPI-2 (10 µg/lane), expressed
and purified as described in Methods, was applied to 15% SDS-PAGE
analysis under reducing (Red.) and nonreducing (Non-Red.) condi-
tions. Proteins were visualized by silver staining. The positions of the
molecular-weight markers are indicated on the left.bated with either rabbit anti-human TFPI-2 Ab or
nonimmunized rabbit IgG (18 hour, 4°C), and precip-
itated by subsequent addition of goat anti-rabbit IgG
(18 hour, 4°C; Jackson ImmunoResearch Laboratories
Inc.) and protein A-Sepharose beads (2 hours, 4°C;
Pharmacia Biotech Inc., Piscataway, New Jersey, USA).
The precipitates and the original supernatants were
separated by SDS-PAGE and applied to either zymog-
raphy or Western blot analysis. For zymographic
analysis, gels were washed twice (15 minutes) with
2.5% Triton X-100 and incubated (24 hours, 37°C) in
zymography buffer (50 mM Tris HCl, 10 mM CaCl2,
50 mM NaCl, 0.05% BRIJ 35). Gels were stained using
Coomassie Brilliant Blue R-250 (Sigma Chemical Co.).
Clear areas on the Coomassie-stained gel indicated
sites of gelatinolysis.
Immunohistochemistry. Atherosclerotic plaques from
human coronary and carotid arteries (n = 12) and
nonatherosclerotic arteries (n = 5) were obtained from
transplantation donors, at endarterectomy and at
autopsy. Air-dried serial cryostat sections (6 µm) were
fixed in acetone (5 minutes, –20°C), preincubated
with PBS/0.3% H2O2, and incubated (30 minutes)
with primary or control Ab (mouse myeloma protein
MOPC-21; Sigma Chemical Co.; or rabbit IgG). Sub-
sequent processing was performed according to the
manufacturer’s recommendations (Universal DAKO
LSAB peroxidase kit; DAKO Corp., Carpinteria, Cali-
fornia, USA). Ab binding was visualized with 3-amino-
9-ethyl carbazole (AEC; Sigma Chemical Co.). For
colocalization of TFPI-2 with the respective cell types
or MMPs, double-immunofluorescence staining was
performed. Frozen sections were incubated with rab-
bit anti-human TFPI-2 Ab (90 minutes), followed by
biotinylated secondary goat anti-rabbit Ab (45 min-
utes; Vector Laboratories, Burlingame, California,
USA) and streptavidin conjugated with Texas red (30
minutes; Amersham Pharmacia Biotech Inc.). Subse-
quently, specimens were treated with an avidin-
biotin–blocking kit (Vector Laboratories), washed,
and stained with monoclonal cell type- or MMP-spe-
cific Abs (24 hours, 4°C), biotinylated secondary
horse anti-mouse Ab, and finally FITC-conjugated
streptavidin (30 minutes) (Amersham Pharmacia
Biotech Inc.). Nuclei were stained blue with bisbenz-
imide (Calbiochem-Novabiochem Corp.).
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Figure 2
TFPI-2 inhibits processing of triple-helical type I collagen (Col I) by interstitial collagenases. Purified human triple-helical type I collagen
(100 µg/ml) was incubated (24 hours, 25°C) with either MMP-1 (a) or MMP-13 (b) (both at 10 µg/ml) preincubated with the respective
concentration of TFPI-2 or TIMP-1, or (c) incubated with MMP-1 and MMP-13 (both at 10 µg/ml) preincubated with TFPI-2 (100 µg/ml)
complexed (45 minutes, 37°C) with VIIa/TF (20 nM). Reactions were applied to Western blot analysis with anti–type I collagen Ab. (d)
Human recombinant MMP-1 or MMP-13 (both at 10 µg/ml) were incubated with TFPI-2 (100 µg/ml) complexed with the respective con-
centrations of VIIa/TF, and the subsequent ability of the MMPs to process native fluorogenic substrate was measured as described. Per-
centage of activity was normalized to the activity obtained with the respective MMP lacking TFPI-2. Data shown represent mean ± SD and
are representative of at least three independent experiments.Results
TFPI-2 inhibits MMP activity. To determine whether
TFPI-2 inhibits MMP activity directly, varying concen-
trations of human recombinant TFPI-2 were preincu-
bated with activated recombinant MMP-1 (1 hour,
37°C) before addition of fluorophore-conjugated
native type I collagen substrate. TFPI-2 concentration
dependently inhibited MMP-1–mediated (10 µg/ml,
corresponding to 200 nM MMP-1) collagenolysis (Fig-
ure 1a) with a median effective dose (EC50) of 1.6 ±0.53
µg/ml, corresponding to approximately 57.6 ±19.1 nM
TFPI-2 (n = 10). Maximal inhibition (85.9% ± 0.23%; 
n = 10) was observed with 9.6 ± 5.2 µg/ml TFPI-2 
(345 ± 187 nM). Since we recently provided evidence
for interstitial collagenolysis by MMP-13 within
human atheroma (9), we analyzed TFPI-2’s effect on
this MMP as well. TFPI-2 diminished MMP-13 activi-
ty (10 µg/ml) in a stoichiometric fashion similar to
that observed for MMP-1, achieving similar maximal
inhibition (Figure 1b) with an EC50 of 0.876 ± 261
µg/ml, corresponding to approximately 31.5 ± 9.4 nM
TFPI-2 (n = 4). TFPI-2 and TIMP-1 had similar
inhibitory stoichiometry (Figure 1, e and f). It remains
to be determined whether the incomplete inhibition of
MMP activity by TFPI-2 is due to insufficient inhibito-
ry capability or to assay background, although the
finding that TIMP-1 in the same assays yielded similar
maximal inhibition supports the latter explanation.
We investigated further whether TFPI-2 inhibited
downstream mediators of collagenolysis. This serpin
inhibited the gelatinases MMP-2 and MMP-9 less effec-
tively and potently than it did interstitial collagenases
(Figure 1, c and d). Maximal inhibition of the gelati-
nases (10 µg/ml) required 58.9 ± 17.1 µg/ml (2.1 ± 0.6
µM) and 63.4 ± 20.0 µg/ml (2.3 ± 0.7 µM), lowering
activity of MMP-2 to 40% ±14.6% (n= 6) and of MMP-9
to 37% ± 14.4% (n = 6), respectively. The median effec-
tive concentration corresponded to 15.3 ± 3.4 µg/ml
(551 ± 122 nM) and 14.1 ± 4.8 µg/ml (508 ± 173 nM)
TFPI-2 for MMP-2 and MMP-9, respectively. A similar-
ly effective inhibition of gelatinase required a molar
ratio of 3:1 of TIMP-1/MMP (data not shown).
Control experiments demonstrated inactivity of
MMP-2 and MMP-9 in the collagenase assay (data not
shown). Moreover, nonactivated MMP-1 or MMP-13
did not exhibit gelatinolytic activity, eliminating the
possibility that other enzymes, e.g., serine proteinases,
could account for the ECM-degrading activity provid-
ed by the MMP-preparations employed. APMA-acti-
vated MMP-1 and MMP-13 did have some gelatinolyt-
ic activity, though considerably less than MMP-2 or
MMP-9 (data not shown). Moreover, TFPI-1 did not
affect MMP activity, and TFPI-2 alone did not affect
fluorescence intensity or optical density in any of the
assays used (data not shown). To determine the speci-
ficity of TFPI-2–mediated inhibition, cathepsins S and
K were applied to processing assays identical to those
employed for MMPs, but using elastin as the native
substrate. TFPI-2 did not affect the elastolytic activity
of either cathepsin, even at concentrations as high as
50,000 ng/ml (Figure 1g).
To explore further the capacity of TFPI-2 to diminish
collagenolysis, the degradation of triple-helical type I col-
lagen by either MMP-1 or MMP-13 preincubated with or
without the serpin was analyzed by Western blotting.
Treatment of interstitial collagen with these MMPs
yielded the expected three-quarter–length cleavage prod-
uct and loss of the immunoreactive full-length type I col-
lagen. Similar to the fluorogenic assays, TFPI-2 concen-
tration dependently inhibited the cleavage of type I
The Journal of Clinical Investigation | May 2001 | Volume 107 | Number 9 1121
Figure 3
Differential expression of TFPI-2 in cultured
SMCs and MØs. (a) Human vascular SMCs
were cultured in IT medium (24 hours) and
either stimulated 24 hours with the respective
concentrations of IL-1β/TNF-α(left), or stim-
ulated for the indicated times with 10/50
ng/ml IL-1β/TNF-α (middle) or 10 µg/ml
CD40L (right). (b) Mononuclear phagocytes
(MØ) were cultured for either 0, 1, 3, or 11
days in RPMI-1640 medium supplemented
with 5% human serum. Before (24 hours)
stimulation with LPS (100 ng/ml), cells were
cultured in serum-free medium. SMC and MØ
culture lysates (30 µg/lane) and SMC super-
natants (SN) were applied to Western blot
analysis employing α–TFPI-2. The positions of
the molecular-weight markers are indicated
on the left. Comparable data were obtained
employing cells from four different donors.collagen by both interstitial collagenases (Figure 2). As
already demonstrated in the fluorogenic assays, TFPI-2
inhibited both collagenases with stoichiometry similar
to TIMP-1 (Figure 2, a and b). Interestingly, preincubat-
ing TFPI-2 with VIIa/TF (Figure 2) or with trypsin (data
not shown), did not diminish the inhibitory capacity of
the serpin against MMP-1 or MMP-13 in either the puri-
fied (Figure 2c) or fluorogenic (Figure 2d) type I collagen
assay, indicating that inhibition of MMPs and serine
proteinases employs different domains of TFPI-2.
Human vascular SMCs and MØs differentially express 
TFPI-2 in vitro. Further experiments analyzed the expres-
sion of TFPI-2 by SMCs and MØs, established sources
of MMPs in human atheroma. Cultured human vascu-
lar SMCs expressed cell-associated TFPI-2 constitutive-
ly (Figure 3, top), with the majority of the inhibitor
localizing in the ECM (data not shown), as previously
reported for EC (4). Stimulation with the inflammato-
ry cytokines IL-1β and TNF-α concentration and time
dependently enhanced the constitutive cell-associated
expression of TFPI-2 and furthermore induced the
release of the inhibitor. In contrast, another potent ago-
nist for MMP expression in SMCs, CD40L, did not
appreciably induce either cell-associated TFPI-2 or
release of the inhibitor, even in concentrations up to 10
µg/ml (Figure 3, top). None of these stimuli affected cell
number or viability (data not shown).
Since MØs probably comprise the major source of MMPs
in human atheroma, we examined TFPI-2 expression by
this cell type as well. Stimulation with IL-1β, TNF-α,
CD40L (data not shown), or LPS (Figure 3b) did not sub-
stantially affect the constitutive expression of TFPI-2 in
freshly isolated peripheral blood mononuclear phagocytes.
Culture of these cells for 3 days diminished expression of
immunoreactive TFPI-2, which became undetectable after
prolonged culture. Thus, regulation of this endogenous
inhibitor inversely correlates to the expression of the inter-
stitial collagenases MMP-1 and MMP-13 during MØ dif-
ferentiation, as published previously (9).
To investigate potential mechanisms of TFPI-2–medi-
ated inhibition of MMP activity, SMC culture super-
natants were immunoprecipitated with anti–TFPI-2 Ab.
Indeed, anti–TFPI-2 coprecipitated gelatinolytic activi-
ty with an apparent molecular weight of 72 kDa and 92
kDa, corresponding to the expected molecular weight
of MMP-2 and MMP-9, demonstrating protein/protein
interactions between TFPI-2 and MMPs (Figure 4a).
Control nonimmune rabbit IgG did not coprecipitate
gelatinolytic activity, demonstrating specificity of the
Ab employed (Figure 4a). Moreover, anti–TFPI-2 copre-
cipitated the MMP-2 zymogen (Figure 4b), as well as
mature forms of the interstitial collagenases MMP-1
and MMP-13 (Figure 4c) after cell-free coincubation in
vitro of recombinant TFPI-2 with the respective recom-
binant MMP, demonstrating direct interaction between
enzyme and inhibitor. Control experiments showed
that heat-inactivated (10 minutes, 95°C) TFPI-2 lost the
ability to interact with the MMPs tested. Furthermore,
anti–TFPI-2 did not precipitate either MMP directly or
via TFPI-1 (Figure 4, b and c).
TFPI-2 colocalizes with SMCs, but not MØs, in atheromatous
lesions in situ. In accordance with the differential in vitro
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Figure 4
Anti–TFPI-2 coprecipitates MMP-1, MMP-2, MMP-9, and MMP-13. (a) Supernatants of unstimulated (none), IL-1β/TNF-α–stimulated
(10/50 ng/ml), or CD40L-stimulated (10 µg/ml) human vascular SMCs were immunoprecipitated with anti–TFPI-2 (α–TFPI-2) or rabbit
Ig (rb Ig), and the precipitates as well as the original culture supernatants (SN) were analyzed by SDS-PAGE zymography. Clear areas indi-
cate gelatinolysis. Comparable data were obtained employing SMCs from three different donors. (b) Recombinant MMP-2 precursor as
well as (c) active MMP-1 (top) and MMP-13 (bottom) (all 10 µg/ml) were incubated (1 hour, 37°C) with recombinant TFPI-2 (50 µg/ml).
Reactions were immunoprecipitated with anti–TFPI-2 and analyzed by Western blotting for the respective MMP. For control purposes heat-
inactivated recombinant TFPI-2 (i.a. recTFPI-2), recombinant TFPI-1 (50 µg/ml), or α–TFPI-1 was applied. The positions of the molecu-
lar-weight markers are indicated on the left.regulation of TFPI-2 expression in SMCs and MØs, cells
considered major producers of MMPs within human
atheroma, we also observed differential expression of
this endogenous inhibitor in these cell types in athero-
sclerotic lesions in situ. Immunohistochemical analysis
demonstrated that TFPI-2 colocalizes with SMCs in
both the tunica media of normal arteries and the media
beneath the fibrous cap overlying atheromatous lesions
(Figure 5, a and b). Staining for the inhibitor in SMCs
within diseased tissue appeared more intense than
staining in the nonatherosclerotic media (data not
shown). In contrast, MØ-enriched areas, such as the
shoulder region of the plaque, stained weakly, if at all,
for TFPI-2 (Figure 5c). TFPI-2 further colocalized with
ECs, an established source for this Kunitz-type inhibitor
(4), with microvascular EC exhibiting particularly
intense staining (data not shown).
Because TFPI-2 coprecipitated with MMPs in vitro
(Figure 4), we further investigated whether MMPs and
TFPI-2 colocalize in situ. Although MMP-2 (Figure 6a)
and MMP-9 (Figure 6b) colocalized with TFPI-2, the
proteinases localized predominantly within the MØ-
enriched shoulder region, whereas TFPI-2 mostly
localized in the SMC-enriched fibrous cap of the
lesion, as determined by immunofluorescence double-
staining (Figure 6c). As with the gelatinases,
immunoreactive MMP-1 (red, Figure 6d) and MMP-13
(red, Figure 6e) exceeded levels of TFPI-2 (green) in the
MØ-enriched area of the lesion (right panels), in con-
trast to the prominent presence of the inhibitor in the
SMC-enriched fibrous cap (left panels). These findings
demonstrate differential expression of TFPI-2 and
MMPs within human atherosclerotic lesions, with the
inhibitor predominant in the fibrous cap and sparse
in areas associated with plaque instability and rupture,
although immunohistochemical analysis does not per-
mit strict quantitation. This finding has particularly
important implications with respect to the activity of
MMP-1 and MMP-13, enzymes we recently implicated
in collagenolysis within human atheroma (9).
In support of these in situ observations, extracts from
normal arteries contained more TFPI-2 than did fibrous
plaques, while extracts of atheromatous lesions with
morphologic features of vulnerability expressed even less
TFPI-2. In contrast, atherosclerotic plaques exhibited
more immunoreactive TIMP-1 and TIMP-2 than
nondiseased arteries (Figure 6f). Thus, expression of
TFPI-2, but not of TIMP-1 or TIMP-2, correlates inverse-
ly with the expression of the interstitial collagenases
MMP-1 and MMP-13 during plaque progression (9).
Discussion
Matrix turnover critically determines the progress of
various diseases, such as cancer, arthritis, and athero-
sclerosis (6, 11, 40, 41). Matrix-degrading enzymes,
such as MMPs, can control ECM content during tumor
metastasis, cartilage deterioration, and arterial lesion
development and complications. Though mechanisms
regulating the enzymatic activity of these proteinases
have major medical ramifications, the processes deter-
mining MMP activity remain incompletely understood.
Previous work by us and others demonstrated that
proinflammatory cytokines, such as TNF-αand IL-1β,
as well as CD40L, induce the expression of MMPs from
atheroma-associated cells (10, 12–16, 42). Enzymatic
function requires activation of MMP zymogens, prob-
ably stimulated by autocatalysis, small molecules (e.g.,
superoxide, peroxynitrite, or hydrogen peroxide), or
proteases (e.g., thrombin, plasmin, or MT-MMPs)
(43–46). However, the expression and release of active
MMP molecules does not establish matrix-degrading
activity, since interactions with ubiquitous endogenous
inhibitors determine enzymatic function in tissues. In
this regard, most attention has focused on the TIMP
family (19–25). However, previous work from several
groups also implicated members of the serpin super-
family, i.e., α2-macroglobulin and RECK, in the regula-
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Figure 5
SMCs and MØs differentially express TFPI-2 in human atheroma.
Cryostat sections from nondiseased aortae (Normal) and atheroscle-
rotic carotid atheroma (Athero) were stained for SMCs and MØs
employing (a, b) anti–α-actin and (c) α-CD68, respectively (left pan-
els). Localization of TFPI-2 (right panels) was shown by (a, c) light
microscopy in adjacent sections, or (b) immunofluorescence double
labeling for direct colocalization within the same section (α-actin stain-
ing for SMCs in red; TFPI-2 staining in green). Analysis of surgical spec-
imens obtained from four different donors showed similar results.tion of MMP activity (33–35). The present report
demonstrates inhibition of active MMPs by the serpin
TFPI-2, probably by direct protein/protein interac-
tions, employing domains distinct from those respon-
sible for serine-proteinase inhibition. Moreover, the
findings presented here support the hypothesis that
matrix-bound TFPI-2 in nondiseased tissue favors
ECM stability by inactivating MMPs, and vice versa,
diminished TFPI-2 might allow increased matrix
degradation in plaques, enhancing their susceptibility
to rupture. Accordingly, nonatherosclerotic arterial tis-
sue and its predominant cell type, vascular SMCs, con-
stitutively expressed TFPI-2 in situ and in vitro. Thus,
SMC might contribute to the integrity of the vascular
wall in a dual fashion by functioning as the major
source of ECM (47, 48) and expressing the endogenous
MMP inhibitor TFPI-2. The prominent binding of the
serpin to the ECM probably raises its local effective
concentration. The enhanced TFPI-2 staining of indi-
vidual SMCs within the fibrous cap compared with
those in the media of nondiseased arteries agrees with
the in vitro inducibility of the inhibitor by atheroma-
associated cytokines such as IL-1β  and TNF-α.
Enhanced expression as well as inducible release of
TFPI-2 in response to inflammatory cytokines might
function as additional protection to the SMC-generat-
ed ECM at sites of inflammation.
Furthermore, in accordance with our hypothesis that
lack of TFPI-2 contributes to enhanced matrix degra-
dation in human atheroma, this report demonstrates
diminished TFPI-2, but not TIMP, levels in atheroma-
tous plaques, lesions that contain abundant MMPs (9).
Whether this indeed indicates a more important role for
the serpin than TIMPs in the regulation of MMP activ-
ity remains to be determined, since compartmentaliza-
tion might result in distinct microenvironments with
corresponding variations in MMP/inhibitor ratios. The
relative paucity of TFPI-2 in situ in the shoulder of the
plaque, a region characterized by enhanced collagenol-
ysis as well as enhanced expression of MMP-1 and
MMP-13 (9), may be explained by the diminished
expression of TFPI-2 during differentiation of MØ. This
part of the plaque experiences the highest circumferen-
tial stress and is particularly prone to rupture (49). Inhi-
bition of interstitial collagenases by TFPI-2 has partic-
ular bearing on plaque stability, as these enzymes are
required for the initial step of degradation. In this
regard, the role of MMP-2 as a collagenase (50), a find-
ing disputed by other groups (51), remains uncertain,
since we did not observe collagenolytic activity for either
gelatinase in our collagenolytic assays. Further sup-
porting our hypothesis that TFPI-2/MMP imbalance
crucially determines plaque stability, MØs rather than
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Figure 6
TFPI-2 expression is diminished in the shoulder region of human ath-
erosclerotic plaques. (a, b) Shown are single-wavelength filter pho-
tomicrographs (×10) of cryostat sections from atherosclerotic carotid
atheroma applied to double-immunofluorescence labeling to colo-
calize (a) MMP-2 or (b) MMP-9 (both red) with TFPI-2 (green) with-
in the SMC-enriched fibrous cap. (c) Triple-immunofluorescence
labeling colocalized MMP-2 (red) with TFPI-2 (green) within the
plaque’s shoulder region (left: ×4, right: ×10). Nuclei are stained in
blue. High-magnification photomicrographs (×40) demonstrated dif-
ferential expression of (d) MMP-1 or (e) MMP-13 (both red) with
TFPI-2 (green) in SMC-enriched (left) or MØ-enriched (right) areas of
human atheroma; nuclei are stained in blue. (f) Protein extracts from
frozen tissue of nonatherosclerotic carotid arteries (Normal), as well
as carotid plaques dichotomized into lesions displaying features asso-
ciated with either stable (Fibrous) or vulnerable (Athero) plaques,
were analyzed by Western blotting employing α–TIMP-1 (top),
–TIMP-2 (middle), or –TFPI-2 (bottom). Analysis of five normal arter-
ies, five fibrous and seven atheromatous surgical specimens of athero-
ma from different donors showed similar results.SMCs appear to elaborate the bulk of the matrix-
degrading enzymes, particularly interstitial collagenas-
es, in human atheroma (9, 10, 52–54). Aside from the
diminished expression in differentiated macrophages,
decreased levels of total immunoreactive TFPI-2 in
plaques probably result from fewer numbers of SMCs
rather than diminished expression of TFPI-2 per SMC
because (a) cytokines present in atheroma increase
TFPI-2 expression by SMC in vitro,and (b) accordingly,
TFPI-2 expression in situis actually increased in SMCs
within the fibrous cap of human atheroma compared
with that in nondiseased arterial tissue.
Demonstrating that TFPI-2 limits the enzymatic
activity of MMPs also suggests a mechanism by which
TFPI-2 reduced matrix degradation by highly invasive
fibrosarcoma cells, which could not penetrate Matrigel
in the presence of this serpin (36). Thus, these findings
indicate a new biological role for TFPI-2 as an inhibitor
of matrix degradation in atherosclerosis as well as other
chronic inflammatory diseases, such as cancer.
A previous study indicating that TFPI-2 might par-
ticipate in matrix-protective processes described inhi-
bition of plasmin-dependent activation of MMP
zymogens by TFPI-2 (5). However, the mechanism
remained unclear. The present data established that
TFPI-2 and MMPs can interact by direct protein/pro-
tein interactions, probably involving sites of interac-
tion distinct from those responsible for the inhibition
of serine proteinases. In addition to inhibiting plasmin
directly, the serpin TFPI-2 might therefore prevent
plasmin-dependent activation by binding to pro-
MMPs, either sterically hindering plasmin or altering
the MMP zymogen allosterically.
Furthermore, the surprising finding that the serpin
TFPI-2 inhibits nonserine proteinases might be
explained by potential molecular mechanism of inhibi-
tion resembling those acting in TIMPs. TIMPs are com-
prised of two domains, each containing three disulfide
bonds thought to coordinate the requisite Zn+ion in the
MMP active site (23). Similarly, TFPI-2 contains three
domains that also contain three disulfide bonds each,
possibly providing a similar inhibitory mechanism.
In summary, the observed expression of TFPI-2 in
SMCs of normal and diseased tissue and diminished
expression of the inhibitor in lesional MØ, in accor-
dance with the in vitro data, supports the hypothesis
that this serpin limits ECM degradation in the
human vascular wall and that the loss of TFPI-2
might promote plaque formation and/or complica-
tion. Whether TFPI-2 acts in concert with other
endogenous MMP inhibitors, such as TIMPs, and
whether TFPI-2 indeed crucially regulates MMP activ-
ity in vivo will require further study.
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